Previous 10 | Next 10 |
2023-12-27 08:30:03 ET Raymond James analyst issues STRONG BUY recommendation for FUSN on December 27, 2023 09:06AM ET. The previous analyst recommendation was Outperform. FUSN was trading at $7.97 at issue of the analyst recommendation. The overall analyst consensus : B...
2023-12-27 07:30:02 ET RBC Capital analyst issues STRONG BUY recommendation for FUSN on December 27, 2023 08:00AM ET. The previous analyst recommendation was Strong Buy. FUSN was trading at $7.97 at issue of the analyst recommendation. The overall analyst consensus : BUY...
2023-12-26 13:10:19 ET More on Actinium Pharmaceuticals Actinium Pharmaceuticals: The Trickle Down Continues, And I Maintain A Buy Seeking Alpha’s Quant Rating on Actinium Pharmaceuticals Historical earnings data for Actinium Pharmaceuticals Financial ...
2023-12-26 12:16:48 ET More on Fusion Pharmaceuticals Fusion Pharma shares jump following expanded actinium supply deal with BWXT Seeking Alpha’s Quant Rating on Fusion Pharmaceuticals Historical earnings data for Fusion Pharmaceuticals Financial infor...
2023-12-26 09:45:08 ET Coinbase Global Inc (COIN) COIN is trading UP for the last 5 days, and it at trading at $177.12 with volume of 3,974,731 and a one day change of $1.64 (0.93%). Coinbase Global Inc has a 52-week low of 32.58 and a 52-week high of $121.46. The business's 50-day ...
Fusion Pharmaceuticals Strengthens Actinium Supply with Onsite Isotope Production through Expanded BWXT Medical Collaboration Canada NewsWire Collaboration enables Fusion to produce high purity actinium-225 at Company's GMP manufacturing facility Agreement furt...
Agreement Furthers BWXT Medical’s Position as a Global Leader in Actinium Supply Collaboration Enables Fusion to Produce High Purity Actinium-225 At Its Manufacturing Facility for Clinical Trials BWXT Medical Ltd. and Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) today annou...
Fusion Pharmaceuticals to Present at Upcoming Investor Conferences Canada NewsWire HAMILTON, ON and BOSTON , Nov. 8, 2023 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmac...
Fusion Pharmaceuticals Inc. (FUSN) is expected to report $-0.4 for Q3 2023
2023-11-07 08:27:16 ET More on Fusion Pharmaceuticals Seeking Alpha’s Quant Rating on Fusion Pharmaceuticals Historical earnings data for Fusion Pharmaceuticals Financial information for Fusion Pharmaceuticals For further details see: Fusion Pharma...
News, Short Squeeze, Breakout and More Instantly...
Fusion Pharmaceuticals Inc. Company Name:
FUSN Stock Symbol:
NASDAQ Market:
Fusion Pharmaceuticals Inc. Website:
Acquisition of Fusion Pharmaceuticals Completed Canada NewsWire HAMILTON , ON and BOSTON , June 4, 2024 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs), a...
Fusion Pharmaceuticals Receives Final Court Order Approving Arrangement Canada NewsWire HAMILTON , ON and BOSTON , May 31, 2024 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation ...
Fusion Pharmaceuticals Shareholders Approve Acquisition by AstraZeneca Canada NewsWire HAMILTON, ON and BOSTON , May 29, 2024 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiocon...